Product Description: Zanoterone is an orally active antagonist of the androgen receptor (AR) with a Ki of 2.2 μM. Zanoterone blocks the binding of androgens such as testosterone and dihydrotestosterone (DHT), inhibiting the androgen signaling pathway, thereby reducing androgen-dependent prostate hyperplasia and prostate cancer growth[1].
Applications: Metabolism-protein/nucleotide metabolism
Formula: C23H32N2O3S
References: [1]Juniewicz PE, et al. Effect of combination treatment with zanoterone (WIN 49596), a steroidal androgen receptor antagonist, and finasteride (MK-906), a steroidal 5 alpha-reductase inhibitor, on the prostate and testes of beagle dogs. Endocrinology. 1993 Aug;133(2):904-13.
CAS Number: 107000-34-0
Molecular Weight: 416.58
Research Area: Cancer; Endocrinology
Solubility: 10 mM in DMSO
Target: Androgen Receptor